![Tai-An Lin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Tai-An Lin formerly worked at EMD Serono, Inc., as Director-Immuno Oncology Translational from 2016 to 2019, Springworks Therapeutics, Inc., as Chief Scientific Officer from 2023 to 2025, and Black Diamond Therapeutics, Inc., as SVP-Translational Science & Discovery Biology.
Dr. Lin received his doctorate degree from the University of Missouri.
Tidigare kända positioner av Tai-An Lin
| Företag | Position | Slut |
|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2025-07-01 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Företagsledare/Principal | 2019-09-01 |
| BLACK DIAMOND THERAPEUTICS, INC. | Företagsledare/Principal | - |
Tai-An Lins utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
7
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
University of Missouri
 University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
